The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
That's Brilliant SOG. I should have said 1802 well progressed in pre clinical. So if 1801 achieves what we expect in P1a, then we are into P2 with 1801 and 1802. This all could happen this year. Then chk1 in combo. The world could be our oyster, everything crossed as they say.
Don't want to jump the gun Brighty, but say we achieved a licencing deal for 1801 of circa $310m, that I would imagine should bring us close to where we were at the height of 2021 of around 9p pre consolidation. Especially as we have 1802 to put straight into a P1a as I understand that the preclinical would have been covered by 1801. (Correct me if that is not so) Don't want to sound outlandish but would 1802 be able to go straight into P2a as would the safety profile of 1801 in people also apply to 1802. (just wondering) Then there is the no small matter of CHK1 to come through hopefully, a molecule that appears extraordinary are in its applicability. Gunner mentioned flt earlier and who knows what AI technology could achieve in increasing it's solubility. (More conjecture from yours truly I have to admit. Imagine if Thoth was still with us, think the yacht brochures would again be thumbed through. Sad isn't it, we could do with optimism, and humour.
Excellent posts this morning. I'm a bit like Benhowell in procrastination in selling. The takeout is cleaner if, of course, the price is right. 300 for a licensing deal in P2 is really good and is close to 12. Should times the current value of the company. I would not be surprised if Tim and Co. are already having on licence discussions with an interested and suitable party(s)should the results on P1a be successful as we hope and expect.
Excellent scientific and financial analysis SOG. We are back in the race again despite the mugging along the way. Its been a bare knukle ride and we have survived it. I think that the scientific expertise shared on this board by you and some others has helped greatly to give the confidence needed to stay invested in this company.
I would expect that this is the beginning of the rerate rather than the beginning of the end with plenty more news to come. On thing is certain and that there is never certainty, but the omens are positive.
We have been through the mill on this and I believe the trap door was being prepared. I think the forces of darkness thought that with the sp on the floor and funding withdrawn, probably as planned, that SAR would fail. Perhaps a share price of aprox 2p was being prepared for the investors on a take it or leave it basis, after which the company would go private and be set up, after the completion of P1a, to be flogged at a massive markup to a pharma.
We deserve to be informed by the BOD who it was who suggested RF and who knew their form. It must have been well known as Puma was telling us all about how it would pan out. Without shareholder participation it is unclear whether we could have survived.
We need to know for the simple reason that how can we be sure thatsuch a scenario won't be hoisted on us again in the future.
Issues like consolidation were imposed on us with no regard for the views of the owners of this company, the shareholders.
I believe that the BOD, while negligent, they did shape up when heel come to shove in organising the recent funding arrangement.
Welcome back SOG and really appreciate giving me the recognition. It was immediately picked up by you and others and importantly Billy Bunter who contacted the company and you rightly mention those who visited the company.You are a shining light on this board SOG. As they say, it's a
long road that has no turning'. This board has been tremendous. Onwards and upwards.
Like your post jazz manner. There are a number of potential breakthroughs for Sareum owing down the tracks on 1801 that should validate the science further. Positive 737 news also hopefully on the way. I firmly believe that the SHs here are fully committed to finding solutions to the Co.pany finances to ensure that progress. I think we are feeling down and that frustration may be I.pa ting on the SP. Ther is a view from Ted Crilly and others that RF are rapidly ridding themselves of their additional shares by forward selling. On very little selling g the SP hS been taken down y 11%. Millions of shares were bought o er the past week. Let's see the bright side of life as the say as we await the news on 1801 patent, 1801 p1 final results, 737 news, partnership or licencing and in the knowledge that we are prepared to step into the brech again. Onwards and upwards for our battered but not broken holders.
The question is could the BOD have raised more to pay off RF. If the answer is yes, then why did they not. A possible next question is is there anything we the shareholders, can do to change course. The next question would calling an EGM be helpful in getting a change of direction.
Peel Hunt have a report out today that the London Stock Exchange, including AIM could be stripped of small companies by 2028 as large well resourced companies prey on smaller weaker less resourced companies.
Would suggest that Peel Hunt look themselves in the mirror.
Agree Num4 and sog. P1 data is key and, if what we anticipate it to be should be, trumpeted from the highest mountain. The shareholders on here stood up and and showed courge and loyalty. The company must now reward that loyalty by massively improving their communication to shareholders and to the wider public. I myself bought some shares on the open market this morning as the offer only applied to UK residents. MHRA, PH, RF. You couldn't make it up. We have been through the wringer on this, it looks like the tide has turned just in time for all genuine holders.
Me thinks the 300,000 wrap retail offer is in response to us on here offering that amount initially to get them over the immediate hurdle with funding. Unfortunately for me it appears that the offer is for UK residence investors only, from what I read. As an alien from the Republic of Ireland, looks like I'm excluded. Will be buying more regardless this afternoon or Tuesday. The RF funding was a scandal unfortunately by those who should have known better.
Excellent research and analysis SOG and HbD. Imagine if we are superior to Deucravacitinib, as illustrated in your post SOG. Agree Hbd, funding should not be an issue. Agree also that BMS would not like to be outflanked by a superior molecule. Well if they want to protect their product they would be obliged to licence 1801 from SAR or go for a buyout. There are other large pharma that may also want a bite at the hugely lucrative market in psoriasis and probably other conditions.
You would wonder in relation to the high number of knockers currently on this BB and ADVEN has been almost totally taken over, save for critical thinker,who used to be on here as steadydanny.
Hope sincerely that anyone on the BOD or the funders have been got at and that we'll have excellent Pa1 results, as anticipated and a satisfactory funding arrangement quickly. Reme.ber the present shareholders are prepared to step up and fund the 300,000 if necessary to get this over the line. The potential is massive, our mplecule potentially best in class, current share price a joke.